Additionally, research has shown evidence for the existence of a TG2/NF-κB signaling loop in breast cancer, the nature of the signal transduction that activates this loop, and phenotypic consequences stemming from its aberrant activation (Brown, 2013). Here, TGM2 is linked to breast carcinoma.